Press Release
Recombinant Vaccines Market 2020 Global Size, Growth Insight, Share, Trends, Industry Key Players, Regional Forecast To 2026
Recombinant Vaccines Market Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments
The global recombinant vaccines market size is projected to reach USD 21.00 billion by the end of 2026. The advancements in molecular genomics have opened up a huge potential for market growth. According to a report by Fortune Business Insights, titled “Recombinant Vaccines Market Size, Share & Industry Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026,” the market size was USD 8.97 billion in 2018. Driven by increasing number of regulatory approvals, the market will exhibit a CAGR of 11.3% during the forecast period, 2019-2026
Request a Sample Copy of the Global Recombinant Vaccines Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/recombinant-vaccines-market-101935
Some of the leading companies that are operating in the global recombinant vaccines market are:
- GlaxoSmithKline plc.
- Merck & Co., Inc
- Pfizer Inc
- Dynavax Technologies
- Sanofi
- Serum Institute of India Pvt. Ltd
- Novartis AG
- Other Prominent Players
Segmentation
By Type
- Subunit
- Live Attenuated
By Route of Administration
- Parenteral
- Oral
By Disease Indication
- Human Papillomavirus
- Hepatitis B
- Rotavirus
- Herpes Zoster
- Meningococcal B
- Others
By Distribution Channel
- Hospitals & Retail Pharmacies
- Government Suppliers
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
December 2019: Merck received USFDA approval for ERVEBO, the first Ebola vaccine. Ervebo is a recombinant viral vaccine that is recommended for the treatment of zaire ebolavirus.
October 2017: USFDA approved GlaxoSmithKline’s new vaccine SHINGRIX which is used for the treatment of herpes zoster.
More Trending Topics From Fortune Business [email protected]
At 7.8% CAGR, Mass Spectrometer Market to be worth more than US$ 10,000 Mn by 2026
